Pasithea Therapeutics Receives FDA IND Clearance for PAS-004
FDA clearance allows the company to advance PAS-004 for neurofibromatosis type 1-associated cutaneous neurofibromas.
Story updates
12:09:40 PM UTC
SquawkNews
Pasithea Wins FDA Clearance for Phase 2 Trial of PAS-004 in Cutaneous Neurofibromas Pasithea The